Clinical Trials · NCT00747500

Non Interventional Post Marketing Programme in Acromegaly

Phase
N/A
Recruitment status
Completed
Sponsor
Ipsen
Enrollment
42
Start date
Jul 2008
Locations
7 sites, United Kingdom
Primary endpoint
safety and local tolerability of Somatuline Autogel when administered by patients or their partners or from a healthcare professional
View Lanreotide compound reference